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BACKGROUND: Fludarabine plus busulfan (FB) and fludarabine plus melphalan (FM) are 2 widely used reduced-intensity conditioning
(RIC) regimens for allogeneic hematopoietic stem cell transplantation (allo-SCT). METHODS: The current survey compared transplan-
tation outcomes for a cohort of 394 acute myeloid leukemia (AML) patients given bone marrow or peripheral blood stem cells from
human leukocyte antigen–identical siblings after FB (n5218) or FM (n5 176). Patients given manipulated grafts and those given T-
cell–depleting agents (anti-thymocyte globulins or alemtuzumab) were not included. RESULTS: At the time of transplantation, 266
patients (68%) were experiencing their first complete remission (CR), 69 (18%) were experiencing a later CR, and 59 (15%) had
advanced disease. The incidences of acute and chronic graft-versus-host disease were similar in the 2 groups of patients. The 2-year
relapse incidence (RI), nonrelapse mortality (NRM) rate, leukemia-free survival (LFS) rate, and overall survival (OS) rate were
31%63%, 18%63%, 51%64%, and 54%64%, respectively, for FB patients and 20%63% (P5.007), 20%63% (P5.4), 60%64%
(P5.08), and 62%64% (P5.2), respectively, for FM patients. Among FB patients given intravenous busulfan (n581), the 2-year RI,
NRM, LFS, and OS rates were 26%65% (P5.43 vs FM patients), 25%66% (P5.18), 49%67% (P5.07), and 54%67% (P5 .13), respec-
tively. In multivariate analyses, FM was associated with a lower RI (hazard ratio [HR], 0.5; P5.01) and a trend toward higher NRM
(HR, 1.6; P5.1) with similar LFS (HR, 0.8; P5.2) and OS (HR, 0.9; P5.6). CONCLUSIONS: These results suggest that although FM pro-
vides better AML control than FB as an RIC regimen for allo-SCT, the 2 regimens provide similar survival. Multicenter randomized
studies are needed to confirm these findings. Cancer 2014;000:000-000. VC 2014 American Cancer Society.
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INTRODUCTION
Despite major advances in the field such as the development
of demethylating agents,1 the outcome for older patients with
acute myeloid leukemia (AML) fit for intensive chemother-
apy has remained dismal.2 Allogeneic hematopoietic stem cell
transplantation (allo-SCT) after reduced-intensity condition-
ing (RIC) is increasingly recognized as a good treatment
option for select patients with intermediate/high-risk AML
who are unfit for classical myeloablative conditioning.3-7 This
approach, which relies mainly on immune-mediated graft-
versus-tumor effects for leukemic eradication,8-12 is feasible in
patients with a good general status up to 75 years of age.8,13,14
Fludarabine with intermediate doses of busulfan (flu-
darabine plus busulfan [FB])10 and fludarabine with inter-
mediate doses of melphalan (fludarabine plus melphalan
[FM])9 are 2 widely used RIC regimens.15-18 A prior single-
center study reported by Shimoni et al19 compared trans-
plantation outcomes in a cohort of 151 patients with various
hematological malignancies given grafts after FB (n5 72) or
FM (n5 79). Although a higher proportion of patients
with B-cell malignancies were given FM and a higher pro-
portion of patients with myeloid malignancies were condi-
tioned with FB, the study demonstrated more hematological
and nonhematological toxicities, a higher incidence of non-
relapse mortality (NRM), and a lower relapse incidence (RI)
in FM patients. Furthermore, among patients undergoing
transplantation in complete remission (CR), overall survival
(OS) was better for FB patients versus FM patients because
of lower NRM.19 The current survey compared FB and FM
in a homogeneous cohort of 394 AML patients given grafts
from human leukocyte antigen (HLA)–identical siblings. In
an attempt at minimizing possible confounding factors,
patients given manipulated grafts and those administered in
vivo T-cell depletion (with anti-thymocyte globulin [ATG]
or alemtuzumab) were not included. The main observations
were that the FM regimen was associated with lower RI
than FB and also with a trend for higher NRM. A similar
suggestion of higher RI was also observed when only patients
given intravenous busulfan were considered in the FB group
(n5 81), although the difference no longer reached statisti-
cal significance, perhaps because of the lower statistical
power due to the lower number of patients or because of the
higher anti-AML activity of the intravenous formulation.
Importantly, OS and leukemia-free survival (LFS) did not
significantly differ between FB and FM patients.
MATERIALS AND METHODS
Data Collection
This survey was a retrospective study performed by the
Acute Leukemia Working Party (ALWP) of the European
Group for Blood and Marrow Transplantation (EBMT).
The EBMT registry is a voluntary working group of more
than 500 transplant centers; its participants are required
once a year to report all consecutive stem cell transplants
and follow-up. The scientific board of the ALWP
approved this study. The population selection criteria
included primary or secondary AML, first allo-SCT from
an HLA-identical sibling between 2000 and 2012, bone
marrow or granulocyte colony-stimulating factor–mobi-
lized peripheral blood stem cells as a stem cell source, and
FB (with a total busulfan dose ranging from 7.1 to
8.9 mg/kg [oral] or from 6.0 to 6.9 mg/kg [intravenous])
or FM (with a total melphalan dose ranging from 130 to
150 mg/m2). The population exclusion criteria included
another chemotherapy drug or total body irradiation in
the conditioning regimen and in vivo (ATG or alemtuzu-
mab) or in vitro T-cell depletion. We elected to exclude
matched unrelated donor allo-SCT recipients to avoid
confounding factors for analyses comparing RI, NRM,
and graft-versus-host disease (GVHD) between the 2
groups and because the vast majority of unrelated recipi-
ents received in vivo T-cell depletion with ATG or alem-
tuzumab. The grading of acute and chronic GVHD was
performed with established criteria.20 For the purpose of
this study, all necessary data were prospectively collected
according to EBMT guidelines and with EBMT mini-
mum essential data forms.
Statistical Analyses
Data from all patients meeting the inclusion/exclusion
criteria were included in the analyses. The start time was
the date of transplantation for all endpoints. To evaluate
RI, patients dying either from direct toxicity of the proce-
dure or from any other cause not related to leukemia were
censored. NRMwas defined as death in CR. Patients were
censored at the time of relapse or last follow-up. Cumula-
tive incidence functions were used for RI and NRM in a
competing risk setting because death and relapse were
competing together.
For estimating the cumulative incidence of chronic
GVHD, death was considered a competing event. OS and
LFS rates were calculated with Kaplan-Meier estimates.
Univariate analyses were performed with Gray’s test for
cumulative incidence functions and with the log-rank test
for OS and LFS. Associations of patient and graft charac-
teristics with transplantation outcomes (chronic GVHD,
RI, NRM, LFS, and OS) were evaluated in multivariate
analyses with Cox proportional hazards. The factors
included in the Cox models were FM versus FB, CR ver-
sus no CR at transplantation, female donor to male
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recipient versus other sex combinations, donor and recipi-
ent seronegativity for cytomegalovirus (CMV) versus
other combinations, secondary AML versus primary
AML, postgrafting immunosuppression with cyclospo-
rine alone versus other, a year of transplantation more
recent than the median (2008), and an age at transplanta-
tion greater than the median (56 years). All tests were 2-
sided. The type I error rate was fixed at 0.05 for the deter-
mination of factors associated with time-to-event out-
comes. Statistical analyses were performed with the SPSS
19 (SPSS, Inc, Chicago, IL) and R 2.13.2 software pack-
ages (R Development Core Team, Vienna, Austria).
RESULTS
Patients
Data from 394 patients were included. Their characteris-
tics are given in Table 1. Briefly, the median patient age at
transplantation was 56 years (range, 21-76 years). The
median time from diagnosis to transplantation was 165
days. Among patients with cytogenetic data available at
diagnosis (n5 239 or 61%), 8% had good-risk cytogenet-
ics, 76% had intermediate-risk cytogenetics, and 17%
had high-risk cytogenetics. Among FB patients
(n5 218), 137 patients were given oral busulfan, and 81
were given intravenous busulfan (including 59 patients in
their first CR, 15 patients in their second CR or a later
CR, and 7 patients with advanced disease at the time of
transplantation). In comparison with FB patients
(n5 218), those treated with FM (n5 176) were younger
(median age at transplantation, 54 vs 58 years; P< .001),
underwent transplantation earlier and thus had longer
follow-up (median follow-up, 42 vs 18 months;
P< .001), were less likely to be male patients given grafts
from female donors (20% vs 27%, P5 .05), were less
likely to have secondary AML (5% vs 11%, P5 .03), had
advanced disease more frequently (20% vs 11%, P5 .05),
were more frequently CMV-seronegative and given grafts
from CMV-seronegative donors (18% vs 9%, P5 .009),
and were more likely to have received cyclosporine alone
as GVHD prophylaxis (21% vs 8%, P5 .001). Other
characteristics such as the cytogenetic risk, source of stem
cells, and interval from diagnosis to transplantation were
similar between the 2 groups.
Engraftment and GVHD
Three FB patients but no FM patients failed to experience
engraftment. The median time for reaching 500 neutro-
phils was 17 days (1-50 days) for FB patients and 14 days
(9-43 days) for FM patients (P< .001), probably because
of the more frequent use of methotrexate in FB patients.
The proportions of patients with grade I, II, III, and IV
acute GVHD among FB and FM patients were 12% and
14%, 14% and 16%, 5% and 7%, and 4% and 3%,
respectively (P5 .7). At 2 years, the cumulative incidence
of chronic GVHD was 54%6 4% for FB patients and
48%6 4% for FM patients (P5 .15). After adjustments
for variables with different distributions for FB and FM,
the incidence of chronic GVHD remained similar for FM





Patient age, median (range), y 58 (23-76) 54 (21-71) <.001





Recipient sex: male, n (%) 124 (57) 83 (47) .06
Donor sex: male, n (%) 111 (51) 95 (54) .6
Female donor/male
recipient, n (%)
59 (27) 36 (20) .05
Time from diagnosis to
SCT, median, d
178 157 .12
Secondary AML, n (%) 23 (11) 8 (5) .03
Status at transplantation,
n (%)
CR1 155 (71) 111 (63) .05
CR21 39 (18) 30 (17)
Advanced 24 (11) 35 (20)
Cytogenetics, n (%)
Good riskc 9 (7) 9 (8) .87
Intermediate riskd 99 (76) 82 (76)
High riske 23 (18) 17 (16)
Not reported/failed 87 68
CMV D2/R2, n (%) 19 (9) 32 (18) .009
Stem cell source, n (%)
G-CSF–mobilized peripheral
blood stem cells
194 (89) 158 (90) .8
Bone marrow 24 (11) 18 (10)
Postgrafting immunosuppression,
n (%)
CSA alone 18 (8) 37 (21) .001
CSA1MTX 134 (61) 83 (47)
Other 66 (30) 56 (32)
CSA1 MMF 42 53
Tacrolimus1MMF 12 2
Other 12 1
Abbreviations: AML, acute myeloid leukemia; CMV, cytomegalovirus; CR1,
first complete remission; CR21, second or later complete remission; CSA,
cyclosporine A; D2/R2, donor-seronegative/recipient-seronegative; Flu-Bu,
fludarabine and busulfan reduced-intensity conditioning; Flu-Mel, fludara-
bine and melphalan conditioning; G-CSF, granulocyte colony-stimulating
factor; MMF, mycophenolate mofetil; MTX, methotrexate; SCT, stem cell
transplantation.
a This group included 137 patients given oral busulfan (with the total busul-
fan dose ranging from 7.1 to 8.9 mg/kg) and 81 patients given intravenous
busulfan (with the total busulfan dose ranging from 6.0 to 6.9 mg/kg). The
81 patients included 59 patients in CR1, 15 patients in CR21, and 7
patients with advanced disease at the time of transplantation.
bP values were calculated with v2 statistics for categorical variables and
with the Mann-Whitney test for continuous variables.
cGood risk was defined as t(8;21), t(15;17), inv or del(16), or acute promy-
elocytic leukemia (these abnormalities only or combined with others).
d Intermediate risk was defined as all cytogenetics not belonging to the
good- or high-risk categories (including trisomies).
eHigh risk was defined as 11q23 abnormalities, a complex karyotype, and
abnormalities of chromosomes 5 and 7.
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and FB patients (hazard ratio [HR], 0.8; 95%CI, 0.6-1.1;
P5 .13).
RI, NRM, LFS, and OS
Two-year RI, NRM, LFS, and OS rates for FB and FM
patients were 31%6 3% and 20%6 3% (P5 .007),
18%6 3% and 20%6 3% (P5 .4), 51%6 4% and
60%6 4% (P5 .08), and 54%6 4% and 62%6 4%
(P5 .2), respectively. Among FB patients given intrave-
nous busulfan (n5 81), the 2-year RI, NRM, LFS, and
OS rates were 26%6 5% (P5 .4 in comparison to FM
patients), 25%6 6% (P5 .18), 49%6 7% (P5 .07),
and 54%6 7% (P5 .13), respectively. When we re-
stricted the analyses to patients undergoing transplanta-
tion in their first CR (n5 266; Fig. 1), the 2-year RI,
NRM, LFS, and OS rates for FB and FM patients were
28%6 4% and 14%6 3% (P5 .005), 17%6 3% and
22%6 4% (P5 .2), 55%6 5% and 64%6 5%
(P5 .2), and 59%6 4% and 66%6 5% (P5 .5),
respectively. Among FB patients given intravenous busul-
fan (n5 59), the 2-year RI, NRM, LFS, and OS rates
were 22%6 6% (P5 .4 versus FM patients), 23%6 7%
(P5 .5), 55%6 8% (P5 .2), and 60%6 7% (P5 .4),
respectively.
In univariate analyses using data from all included
patients (Table 2), secondary AML versus primary AML
was associated with higher NRM (P5 .02), whereas
advanced disease at transplantation was associated with
higher RI (P< .001), which translated into lower LFS
(P5 .003) and OS (P5 .01). Furthermore, CMV-
seronegative patients given grafts from CMV-seronegative
donors had lower NRM (P5 .01). Finally, patients given
cyclosporine A only as GVHD prophylaxis had better
LFS (P5 .05) and OS (P5 .04).
Figure 1. Outcomes of acute myeloid leukemia patients in their first complete remission who were given grafts after FB or FM:
(A) overall survival (P5.53), (B) leukemia-free survival (P5.19), (C) relapse incidence (P5.005), and (D) NRM (P5.21). Percen-
tages in the figures indicate 2-year results. FB indicates fludarabine plus busulfan; FM, fludarabine plus melphalan; NRM, nonre-
lapse mortality.
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After adjustments for variables having different dis-
tributions between FB and FM and associated with
P< .05 in univariate analyses, RI remained significantly
lower for FM patients versus FB patients (HR, 0.5; 95%
CI, 0.3-0.8; P5 .01), whereas there was a suggestion of
higher NRM for FM patients versus FB patients (HR,
1.6; 95% CI, 0.9-2.7; P5 .1). This translated into similar
progression-free survival (HR, 0.8; 95% CI, 0.6-1.2;
P5 .2) and OS (HR, 0.9; 95% CI, 0.6-1.3; P5 .6) for
FM and FB patients. Other factors influencing transplan-
tation outcomes in multivariate analyses included the fol-
lowing: transplantation for advanced leukemia was
associated with higher RI (HR, 0.3; 95% CI, 0.2-0.5;
P< .001) and lower LFS (HR, 0.5; 95% CI, 0.3-0.8;
P5 .001) and OS (HR, 0.5; 95% CI, 0.4-0.8; P5 .006);
CMV-seronegative patients given grafts from CMV-
seronegative donors were associated with lower NRM
(HR, 0.2; 95% CI, 0.5-0.9; P5 .03), which translated
into better OS (HR, 0.5; 95% CI, 0.3-1.0; P5 .04);
cyclosporine A only as GVHD prophylaxis was associated
with better LFS (HR, 0.5; 95% CI, 0.3-0.9; P5 .03) and
OS (HR, 0.5; 95% CI, 0.3-1.0; P5 .04); and secondary
AML was associated with higher NRM (HR, 2.5; 95%
CI, 1.2-5.3; P5 .01; Table 3).
RI, NRM, LFS, and OS for FB patients and FM
patients according to their disease status at transplantation
are shown in Figures 1 and 2.
DISCUSSION
This study compared 2 widely used RIC regimens in a rel-
atively large cohort of AML patients given grafts from
HLA-identical siblings and no in vivo T-cell depletion (to
avoid confounding factors for analyses comparing relapse
and GVHD between the 2 groups21). The main observa-
tion was that the FM regimen was associated with a lower
RI, and this was in agreement with prior observations by
Shimoni et al19 in a cohort of patients undergoing trans-
plantation for various hematological malignancies. This is
TABLE 2. Univariate Analyses
2-Year Resultsa
n RI, % NRM, % LFS, % OS, %
Age <Median 197 266 3 166 2 5764 6164
>Median 197 266 3 216 3 5364 5564
P .86 .39 .68 .6
Year of Tx <Median 205 246 3 206 3 5563 5863
>Median 189 296 4 156 3 5664 6064
P .32 .41 .73 .93
Patient sex Male 207 296 3 196 3 5264 5564
Female 187 236 3 186 3 5964 6164
P .22 .86 .24 .37
Female donor to male recipient No 297 256 3 166 2 5863 6163
Yes 95 286 5 286 5 4466 4866
P .58 .15 .18 .17
Secondary AML No 363 276 2 176 2 5663 5963
Yes 31 206 7 336 9 47610 47610
P .71 .02 .1 .06
Status at Tx CR1 266 226 3 196 3 5963 6263
CR21 69 266 6 196 5 5467 5367
Active disease 59 466 7 146 5 4067 4667
P .0004 .72 .003 .01
SC source BM 42 366 8 186 6 4668 5168
PBSCs 352 256 2 186 2 5663 5963
P .29 .93 .34 .42
CMV D2/R2 No 330 256 2 206 2 5563 5763
Yes 51 266 7 46 3 7067 7367
P .81 .01 .12 .07
GVHD prevention CSA 55 186 6 106 4 7266 7666
CSA1MTX 217 286 3 196 3 5364 5764
Other 122 276 4 226 4 5165 5365
P .31 .23 .05 .04
Abbreviations: BM, bone marrow; CMV, cytomegalovirus; CR1, first complete remission; CR21, second or later complete remission; CSA, cyclosporine A; D2/
R2, donor-seronegative/recipient-seronegative; GVHD, graft-versus-host disease; LFS, leukemia-free survival; MTX, methotrexate; NRM, nonrelapse mortality;
OS, overall survival; PBSC, peripheral blood stem cell; RI, relapse incidence; SC, stem cell; Tx, allogeneic hematopoietic cell transplantation. Data on female
donor to male recipient were missing in 2 cases while data on CMV D2/R2 were missing in 13 cases.
a Censored at 2 years.
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in line with the fact that FM might be more intense than
FB. Indeed, prior studies comparing outcomes of AML
patients receiving grafts after myeloablative or RIC regi-
mens observed a higher RI in the latter group,22 and this
demonstrates the impact on RI of the dose intensity in the
conditioning regimen for allo-SCT in AML patients.
However, as observed in analyses comparing myeloabla-
tive and RIC regimens, the lower RI observed in our FM
patients did not translate into better OS because of a sug-
gestion of higher NRM in FM patients versus FB patients,
and this was in agreement with Shimoni et al.19 Other
potential explanations for the higher risk of relapse in FB
patients might be a possibly inherent higher anti-AML
potential of melphalan in comparison with busulfan and
the possibility that some patients (especially those given
oral busulfan) might have been underexposed to busulfan
because of the well-demonstrated variability of busulfan
pharmacokinetics.23 Interestingly, a similar suggestion for
higher RI was also observed when only patients given in-
travenous busulfan were considered in the FB group
(n5 81), although the difference no longer reached statis-
tical significance, perhaps because of the lower statistical
power due to lower number of patients or because of the
higher anti-AML activity of the intravenous formulation.
TABLE 3. Cox Models Including Variables Having Different Distributions and Associated With P<.05






Leukemia-free survival FM vs FB .23 0.81 0.57-1.15
CR vs advanceda .001 0.50 0.33-0.76
Female donor to male recipient .32 1.20 0.83-1.74
Year of transplantation>median (2008) .78 1.05 0.75-1.48
Age at transplantation>median .84 0.97 0.69-1.36
CMV D2/R2 vs others .08 0.61 0.35-1.06
Secondary AML .56 1.19 0.67-2.11
CSA alone vs other .03 0.52 0.28-0.95
Overall survival FM vs FB .64 0.92 0.63-1.32
CR vs advanceda .006 0.54 0.35-0.84
Female donor to male recipient .24 1.26 0.86-1.84
Year of transplantation>median (2008) .93 0.98 0.69-1.41
Age at transplantation>median .82 0.96 0.67-1.37
CMV D2/R2 vs others .04 0.52 0.28-0.96
Secondary AML .30 1.37 0.76-2.49
CSA alone vs other .04 0.52 0.27-0.97
Cumulative incidence
of relapse
FM vs FB .01 0.51 0.32-0.82
CR vs advanceda .000005 0.31 0.19-0.52
Female donor to male recipient .73 1.09 0.67-1.77
Year of transplantation>median (2008) .33 1.24 0.80-1.93
Age at transplantation>median .44 0.84 0.54-1.31
CMV D2/R2 vs others .82 0.93 0.50-1.73
Secondary AML .28 0.59 0.23-1.52
CSA alone vs other .27 0.66 0.31-1.39
Cumulative incidence
of nonrelapse mortality
FM vs FB .10 1.57 0.92-2.68
CR vs advanceda .61 1.23 0.55-2.77
Female donor to male recipient .18 1.47 0.84-2.55
Year of transplantation>median (2008) .52 0.84 0.49-1.44
Age at transplantation>median .56 1.17 0.69-1.99
CMV D2/R2 vs others .03 0.21 0.05-0.89
Secondary AML .01 2.54 1.22-5.29
CSA alone vs other .07 0.38 0.14-1.07
Cumulative incidence
of chronic graft-versus-host disease
Flu-Mel vs Flu-Bu .13 0.77 0.55-1.08
CR vs advanceda .11 0.69 0.44-1.09
Female donor to male recipient .72 1.07 0.74-1.53
Year of transplantation>median (2008) .53 0.90 0.65-1.25
Age at transplantation>median .56 1.10 0.79-1.53
CMV D2/R2 vs others .03 0.55 0.32-0.95
Secondary AML .46 1.26 0.68-2.30
CSA alone vs other .04 0.59 0.35-0.97
Abbreviations: AML, acute myeloid leukemia; CMV, cytomegalovirus; CR, complete remission; CSA, cyclosporine A; D2/R2, donor-seronegative/recipient-
seronegative; FB, fludarabine plus busulfan; Flu-Bu, fludarabine and busulfan reduced-intensity conditioning; Flu-Mel, fludarabine and melphalan conditioning;
FM, fludarabine plus melphalan.
Bolded values are significant.
aAdvanced indicates not in CR.
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Although the difference between the 2 groups did
not reach statistical significance, 3 FB patients but none of
the FM recipients experienced graft rejection in the cur-
rent study. This observation is consistent with prior obser-
vations by Valcarcel et al24 and Shimoni et al19: the FB
patients were more likely to have a mixed chimera early af-
ter transplantation than those treated with FM because of
the previously observed association between low donor
chimerism levels and a higher incidence of graft
rejection.25
In contrast to what was observed by Shimoni
et al19 (a higher incidence of GVHD in FM patients),
the incidences of acute and chronic GVHD were similar
for the FB and FM patients in the current study. This
apparent discrepancy between the 2 studies might be
due to the fact that the current survey included only
patients given grafts from HLA-identical siblings,
whereas Shimoni et al’s study also included patients
given grafts from HLA-matched or HLA-mismatched
unrelated donors.
Another finding of the current study was that the use
of cyclosporine alone as GVHD prophylaxis was associ-
ated with better LFS and OS. Although this observation
should be taken with caution because of the low number
of patients (n5 55) given cyclosporine alone as GVHD
prophylaxis in the current survey, it is in agreement with
recent data from Rubio et al26 for patients given grafts
from HLA-identical siblings after ATG and intravenous
busulfan–based RIC. Furthermore, in agreement with
other recent observations from our group for a larger
cohort of patients undergoing transplantation after mye-
loablative conditioning or RIC,27 CMV-seronegative
patients given grafts from CMV-seronegative donors had
lower NRM and better OS in the current series.
Figure 2. Outcomes of acute myeloid leukemia patients not in complete remission at transplantation who were given grafts after
FB or FM: (A) overall survival (P5.02), (B) leukemia-free survival (P5.03), (C) relapse incidence (P5.51), and (D) NRM (P5.16).
Percentages in the figures indicate 2-year results. FB indicates fludarabine plus busulfan; FM, fludarabine plus melphalan; NRM,
nonrelapse mortality.
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In summary, these data suggest that although FM
provides better AML control than FB as an RIC regimen
for allo-SCT, the 2 combinations lead to similar survival
rates. Even though that the current survey included a rela-
tively large cohort of patients, multicenter randomized
studies are needed to confirm these results. Ideally, these
studies should use a fixed dose of busulfan area under the
curve (AUC) in the FB arm.
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